K. Yoshimura

Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study

BackgroundVascular endothelial growth factor (VEGF)-D high have been reported as a negative prognostic marker and potential predictive marker for ramucirumab (RAM) efficacy in metastatic ...

Toshiki Masuishi ;

H. Kawakami ;

T. Tsushima ;

S. Hironaka ;

K. Muro ;

K. Shimozaki ;

H. Yasui ;

T. Esaki ;

Y. Kito ;

K. Sakai ;

K. Nishio ;

H. Shoji ;

S. Mitani ;

K. Shiraishi ;

H. Shimokawa ;

T. Tsuzuki ;

Takeshi Yamada , MD;

S. Kajiura ;

Hidehiko Hara , MD;

E. Baba ;

K. Yamazaki ;

K. Yoshimura ;

06/25/2023

A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy

Background Both docetaxel and paclitaxel are a class of microtubule-stabilizing anticancer agents. Partial cross-resistance between docetaxel and paclitaxel was indicate...

K. Yoshimura ;

Tomo Ando , MD;

K. Nakashima ;

H. Yoshita ;

M. Sakumura ;

M. Nomura ;

M. Muto ;

Y. Horie ;

H. Takeda ;

T. Yoshii ;

Y. Tahara ;

C. Katada ;